A Phase Ⅱ Clinical Trial of CD19 CAR-T Cell Infusion for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2026-08-09
Target enrollment:
Participant gender:
Summary
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells
Injection (CD19 CAR-T) Therapy for R/R B-NHL.
Patients will be given a conditioning chemotherapy regimen of fludarabine and
cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.